Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Neuromyelitis optica].

S Jarius1, B Wildemann

  • 1Neurosciences Group, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom. sjarius@gmx.net

Der Nervenarzt
|October 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An autoantibody signature predictive for multiple sclerosis: evidence at the protein level and association with histopathological lesion types.

Journal of neurology·2026
Same author

Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.

Journal of neurology·2024
Same author

Newly emerging type B insulin resistance (TBIR) during treatment with eculizumab for AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD): fatal outcome.

Journal of neurology·2023
Same author

MOG encephalomyelitis after vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2): case report and comprehensive review of the literature.

Journal of neurology·2022
Same author

The role of the posterior malleolus in the treatment of unstable upper ankle joint injuries - A biomechanical study.

Foot and ankle surgery : official journal of the European Society of Foot and Ankle Surgeons·2022
Same author

Controversy on the treatment of multiple sclerosis and related disorders: positional statement of the expert panel in charge of the 2021 DGN Guideline on diagnosis and treatment of multiple sclerosis, neuromyelitis optica spectrum diseases and MOG-IgG-associated disorders.

Neurological research and practice·2021
Same journal

[When brain abscesses run in the family…].

Der Nervenarzt·2026
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
See all related articles

Neuromyelitis optica (NMO), a rare autoimmune CNS disorder, involves optic neuritis and myelitis. The discovery of aquaporin-4 antibodies aids diagnosis and guides new treatments for better outcomes.

Area of Science:

  • Neuroimmunology
  • Demyelinating diseases of the central nervous system
  • Autoimmune disorders

Context:

  • Neuromyelitis optica (NMO), also known as Devic syndrome, is a rare, relapsing demyelinating disease of the central nervous system.
  • NMO is characterized by optic neuritis and longitudinally extensive myelitis, with brain lesions being less common at onset.
  • Histopathology suggests a humoral autoimmune mechanism, distinguishing NMO from multiple sclerosis.

Purpose:

  • To summarize the key features, diagnostic advancements, and therapeutic strategies for Neuromyelitis Optica.
  • To highlight the significance of NMO-specific autoantibodies against aquaporin-4 (Aqp4).
  • To discuss the implications of recent findings for the prognosis and management of NMO.

Summary:

  • Neuromyelitis optica (NMO) is a rare CNS demyelinating disease presenting with optic neuritis and myelitis.

Related Experiment Videos

  • The identification of NMO-specific antibodies targeting aquaporin-4 (Aqp4) is crucial for diagnosis, classifying NMO as the first CNS inflammatory demyelinating disorder with a defined autoantigen.
  • NMO's distinct autoimmune pathogenesis is supported by histopathology, differentiating it from multiple sclerosis.

    • Impact:

    • The detection of aquaporin-4 antibodies has significantly improved NMO diagnosis.
    • Emerging therapies like plasma exchange and B-cell depletion offer improved long-term prognosis for NMO patients.
    • Understanding NMO as a distinct entity with a defined autoantigen facilitates targeted research and treatment development.